Hemosol Corporate Announcement
July 08 2005 - 5:15PM
PR Newswire (US)
Hemosol Corporate Announcement TORONTO, July 8
/PRNewswire-FirstCall/ -- Hemosol Corp. (NASDAQ:HMSLDNASDAQ:
TSX:NASDAQ:HML) - Pursuant to Nasdaq Marketplace Rule 4350(b)(1)(B)
which requires an issuer that receives an audit opinion that
contains a going concern qualification to make a public
announcement disclosing the receipt of such qualification, Hemosol
Corp. today announced that the auditors' report on Hemosol's
financial statements for the year ended December 31, 2004,
contained in Hemosol Corp.'s Annual Report on Form 20-F for the
year ended December 31, 2004 (filed with the U.S. Securities and
Exchange Commission on June 30, 2005), contained a going concern
qualification. About Hemosol Hemosol is a biopharmaceutical company
focused on the development and manufacturing of biologics,
particularly blood-related proteins. Hemosol has a broad range of
novel therapeutic products in development, including oxygen
therapeutics and protein-based therapeutics to treat certain
infectious diseases, cancers and anemia. For more information visit
Hemosol's website at http://www.hemosol.com/. Hemosol's common
shares are listed on the NASDAQ Stock Market under the trading
symbol "HMSLD" through July 8, 2005, and from July 11, 2005 under
the trading symbol "HMSL". The common shares are also listed on the
Toronto Stock Exchange (TSX) under the trading symbol "HML".
Certain statements concerning Hemosol's future prospects are
"forward- looking statements" within the meaning of the United
States Private Securities Litigation Reform Act of 1995 and other
applicable securities legislation. There can be no assurances that
future results will be achieved, and actual results could differ
materially from forecasts and estimates. Important factors that
could cause actual results to differ materially from forecasts and
estimates include, but are not limited to: Hemosol's ability to
successfully implement the Cascade technology and commercialize
products derived from that technology; Hemosol's ability to obtain
additional financing which is critical to the implementation of the
Cascade technology and to Hemosol's continued viability as a going
concern; Hemosol's ability to obtain regulatory approvals for its
products; Hemosol's ability to successfully complete clinical
trials for its products; Hemosol's ability to enter into
satisfactory arrangements for the supply of materials used in its
manufacturing operations and the sale of resulting products to
customers; technical, manufacturing or distribution issues; the
competitive environment for Hemosol's products and services; the
degree of market penetration of Hemosol's products; Hemosol's
ability to attract and retain clients for its bio-manufacturing
services; the risk that Hemosol may not become profitable; and
other factors set forth in filings with Canadian securities
regulatory authorities and the U.S. Securities and Exchange
Commission. These risks and uncertainties, as well as others, are
discussed in greater detail in the filings of Hemosol with Canadian
securities regulatory authorities and the U.S. Securities and
Exchange Commission. Hemosol makes no commitment to revise or
update any forward-looking statements in order to reflect events or
circumstances after the date any such statement is made.
DATASOURCE: Hemosol Corp. CONTACT: Jason Hogan, Investor &
Media Relations, (416) 361-1331, (800) 789-3419, (416) 815-0080
fax, , http://www.hemosol.com/; Archived images on this
organization are searchable through CNW Photo Archive website at
http://photos.newswire.ca/. Images are free to accredited members
of the media. To request a free copy of this organization's annual
report, please go to http://www.newswire.ca/ and click on
reports@cnw.
Copyright
Hemosol (NASDAQ:HMSLD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hemosol (NASDAQ:HMSLD)
Historical Stock Chart
From Jul 2023 to Jul 2024